PBM
Propel Bio Management Portfolio holdings
AUM
$82.4M
This Quarter Return
+35.53%
1 Year Return
+29.32%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$172M
AUM Growth
+$172M
(+12%)
Cap. Flow
-$9.21M
Cap. Flow
% of AUM
-5.34%
Top 10 Holdings %
Top 10 Hldgs %
90.77%
Holding
27
New
3
Increased
3
Reduced
3
Closed
6
Top Buys
| 1 |
Zevra Therapeutics
ZVRA
|
$1.25M |
| 2 |
Ardelyx
ARDX
|
$1.01M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$963K |
| 4 |
CMPS
Compass Pathways
CMPS
|
$504K |
| 5 |
Akero Therapeutics
AKRO
|
$458K |
Top Sells
| 1 |
Fulcrum Therapeutics
FULC
|
$4.65M |
| 2 |
Abeona Therapeutics
ABEO
|
$3.94M |
| 3 |
Plains GP Holdings
PAGP
|
$1.85M |
| 4 |
Kayne Anderson Energy Infrastructure Fund
KYN
|
$1.52M |
| 5 |
Trevi Therapeutics
TRVI
|
$775K |
Sector Composition
| 1 | Healthcare | 83.54% |
| 2 | Energy | 13.65% |
| 3 | Technology | 2.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Applied Therapeutics
APLT
$71M
| $55.8M | 32.38% | 6,567,858 | – | – |
|
|
2
Plains GP Holdings
PAGP
$3.82B
| $23.5M | 13.65% | 1,272,360 -100,000 | -7% | -$1.85M |
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $15.7M | 9.12% | 869,927 | – | – |
|
4
Achieve Life Sciences
ACHV
$152M
| $11.6M | 6.74% | 2,453,092 | – | – |
|
5
TScan Therapeutics
TCRX
$102M
| $10.4M | 6.03% | 2,087,139 | – | – |
|
|
6
Akero Therapeutics
AKRO
$3.74B
| $9.86M | 5.72% | 343,729 +15,977 | +5% | +$458K |
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $9.13M | 5.3% | 43,032 | – | – |
|
8
Avidity Biosciences
RNA
$5.99B
| $8.2M | 4.76% | 178,500 | – | – |
|
|
9
Ardelyx
ARDX
$1.53B
| $7.38M | 4.28% | 1,070,947 +146,364 | +16% | +$1.01M |
|
10
Telesat
TSAT
$307M
| $4.82M | 2.79% | 365,781 | – | – |
|
|
11
Abeona Therapeutics
ABEO
$350M
| $3.94M | 2.29% | 624,022 -624,022 | -50% | -$3.94M |
|
12
Kymera Therapeutics
KYMR
$2.95B
| $2.67M | 1.55% | 56,359 | – | – |
|
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $2.57M | 1.49% | 133,259 +50,000 | +60% | +$963K |
|
14
Kura Oncology
KURA
$686M
| $2.54M | 1.47% | 130,000 | – | – |
|
|
15
Zevra Therapeutics
ZVRA
$509M
| $1.25M | 0.72% | +179,874 | New | +$1.25M |
|
|
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.24M | 0.72% | 146,381 | – | – |
|
17
Athira Pharma
ATHA
$15.3M
| $666K | 0.39% | 1,492,792 | – | – |
|
|
CMPS
18
Compass Pathways
CMPS
$424M
| $504K | 0.29% | +80,000 | New | +$504K |
|
19
Verrica Pharmaceuticals
VRCA
$52.8M
| $500K | 0.29% | 344,937 -80,000 | -19% | -$116K |
|
|
CYBN
20
Cybin
CYBN
$176M
| – | – | -850,000 | Closed | -$230K |
|
|
21
Fulcrum Therapeutics
FULC
$351M
| – | – | -750,000 | Closed | -$4.65M |
|
|
22
Kayne Anderson Energy Infrastructure Fund
KYN
$2.12B
| – | – | -147,033 | Closed | -$1.52M |
|
|
23
Trevi Therapeutics
TRVI
$883M
| – | – | -260,000 | Closed | -$775K |
|